Anumana.ai: Advancing Cardiac Care with AI-Powered ECG Insights

Anumana.ai is a cutting-edge AI-driven health technology platform developed by Anumana, Inc. in collaboration with nference and Mayo Clinic, dedicated to transforming cardiovascular diagnostics through advanced artificial intelligence. Specializing in software-as-a-medical-device (SaMD) solutions, it leverages a vast, proprietary dataset of 11 million patients and multimodal AI to deliver clinically validated, FDA-cleared algorithms that enable earlier detection of heart conditions like low ejection fraction and cardiac amyloidosis. Its flagship ECG-AI™ LEF algorithm, backed by over 100 peer-reviewed publications and proven in real-world trials, enhances diagnostic accuracy with 84.5% sensitivity and 83.6% specificity, and is integrated into clinical workflows via a secure, zero-footprint web dashboard. Anumana is also pioneering generative AI imaging for perioperative cardiac care and has secured reimbursement eligibility, making it a transformative tool for healthcare providers focused on improving patient outcomes.

Key Features:

• FDA-Cleared ECG-AI™ LEF Algorithm: Detects low ejection fraction from standard 12-lead ECGs with high accuracy.
• Breakthrough Device Designation: Recognized by the FDA for its cardiac amyloidosis detection algorithm.
• Multimodal AI for Cardiovascular Care: Combines ECG, echocardiogram, and clinical data for deeper insights.
• Proprietary Clinical Dataset: Trained on over 100,000 data pairs from a 20+ year dataset of 11 million patients.
• Clinical Validation: Supported by 25+ peer-reviewed studies and the EAGLE trial showing 31% higher LEF detection rates.
• Integration with EHR Systems: Seamless deployment via the ECG Viewer web dashboard within existing clinical workflows.
• PHI-Secure & Regulatory-Compliant: Fully compliant with healthcare privacy standards and FDA requirements.
• Reimbursement-Eligible: Approved for reimbursement under new CPT® codes (0764T and 0765T) effective January 2023.
• Generative AI Imaging & Visualization: Developing next-gen tools for real-time procedural support and cardiac imaging.
• Collaborations with Leading Institutions: Partnerships with Mayo Clinic, Pfizer, and academic medical centers ensure robust, real-world validation.

Pricing: Anumana.ai operates on a subscription-based model tailored for healthcare providers and institutions, with pricing available upon request through a demo or direct inquiry.

Conclusion: Anumana.ai stands at the forefront of AI in cardiology, combining deep clinical research, regulatory excellence, and real-world impact to deliver transformative tools that improve early diagnosis and patient care—making it an essential innovation for modern healthcare systems.